{"url_path":"/sec/sln/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-266705-index.html","accession_number":"0001193125-26-266705","cik":"0001479615","ticker":"SLN","issuer_name":"Silence Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-266705-index.html","primary_entity_key":"0001479615","primary_entity_name":"Silence Therapeutics plc"},"word_count":125,"has_tables":true,"body_markdown":"Item 9.01 Exhibits.\n\n(a)\nExhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Press Release dated June 11, 2026](sln-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nSilence Therapeutics plc\n\nDate: June 11, 2026\n\nBy:\n\n /s/ Iain Ross\n\nName: Iain Ross\n\nTitle: Interim Principal Executive Officer and Chairman of the Board of Directors\n\n(Principal Executive Officer)"}